Novo Nordisk A's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Novo Nordisk A (NVO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Novo Nordisk A vs Its Competitors
- TTM: Trailing 12-month revenue of 309,064M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-84.0% annualized vs trailing 12 months).
- Scale: Novo Nordisk A ranks #8 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 3.1% of industry market cap.
- Peer revenue share: Novo Nordisk A accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NVO Sales vs. its Competitors, Q4 2025
Novo Nordisk A generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 0.7% for Novo Nordisk A. Novo Nordisk A's share of combined industry revenue moved from 1.71% to 1.61%, a loss of 0.10 percentage points.
Novo Nordisk A's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Novo Nordisk A | Yes | Yes | No | No |
| High-Confidence Competitors (29) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 87.50 % (7 of 8) | 100.00 % (8 of 8) | 50.00 % (4 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NVO Stock Performance relative to its Competitors
NVO Stock Performance relative to High-Confidence Competitors
NVO Stock Performance relative to Similar-Size Competitors
NVO Stock Performance relative to Similar Growth & Profitability Competitors
Novo Nordisk A's Comment on Competition and Industry Peers
Novo Nordisk A's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Protagonist Therapeutics inc | Named by the company | 85% |
| Sagimet Biosciences inc | Named by the company | 85% |
| Agios Pharmaceuticals Inc | Named by the company | 85% |
| Better Therapeutics Inc | Named by the company | 85% |
| Embecta Corp | Named by the company | 85% |
| Lineage Cell Therapeutics Inc | Named by the company | 85% |
| Intellia Therapeutics Inc | Named by the company | 85% |
| Sana Biotechnology Inc | Named by the company | 85% |
| Altimmune inc | Named by the company | 85% |
| Dariohealth Corp | Named by the company | 85% |
| IMAB | Named by the company | 85% |
| Novabridge Biosciences | Named by the company | 85% |
| Palatin Technologies Inc | Named by the company | 85% |
| Skye Bioscience Inc | Named by the company | 85% |
| Akero Therapeutics Inc | Named by the company | 85% |
| Corbus Pharmaceuticals Holdings Inc | Named by the company | 85% |
| Agentix Corp | Named by the company | 85% |
| Lumos Pharma Inc | Named by the company | 85% |
| Eli Lilly | Named by the company | 85% |
| Septerna Inc | Named by the company | 85% |
| Biorestorative Therapies Inc | Named by the company | 85% |
| Bright Minds Biosciences Inc | Named by the company | 85% |
| Inventiva S a | Named by the company | 85% |
| Ngm Biopharmaceuticals Inc | Named by the company | 85% |
| Uniqure N v | Named by the company | 85% |
| Xeris Biopharma Holdings Inc | Named by the company | 85% |
| Alnylam Pharmaceuticals Inc | Named by the company | 85% |
| Crispr Therapeutics Ag | Named by the company | 85% |
| Gyre Therapeutics Inc | Named by the company | 85% |
| Mannkind Corporation | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Novo Nordisk A's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.